Amazon affiliate link
Alcohol pads
MED PRIDE, 70% isopropyl, 200 count per listing. An alcohol pad does not establish sterility of a research product.
View on Amazon ↗Pigmentation and sexual health
PT-141 / Bremelanotide
research guide
Bremelanotide, referred to by suppliers as PT-141, is a melanocortin receptor agonist. It is FDA approved under the brand Vyleesi as an on-demand subcutaneous injection for acquired generalized hypoactive sexual desire disorder in premenopausal women, based on the phase 3 RECONNECT trials [1][2]. Longer follow-up from the same trial program assessed safety and efficacy over an extended open-label period [3]. Reign Peptide's PT-141 vials and nasal spray are separate research-chemical products, not the approved Vyleesi injector.
Evidence depends on population and formulation. Literature summary, not clinical peer review.
Looking for the product? Reign listings and business disclosure ↓
Jorge Abreu is not a doctor. This is an educational research summary, not a prescription or a personal dosing plan. Study results do not establish that a supplier product is safe or effective for people. Consult a licensed clinician about medical decisions.
01 · Start with identity
What is PT-141 / Bremelanotide?
Bremelanotide as approved (Vyleesi) is dispensed as a single-use, prefilled autoinjector for a specific FDA-cleared indication in a defined patient population. Reign Peptide sells the same peptide sequence as a lyophilized powder vial or nasal spray for research use, not as the approved autoinjector device, and no bioequivalence between these research formats and Vyleesi was identified in the sources reviewed.
Also searched as: Bremelanotide, Vyleesi, melanocortin receptor agonist
02 · Read the evidence
What the studies reported
01
Phase 3 RECONNECT trials
Two identically designed double-blind, randomized, placebo-controlled phase 3 trials in premenopausal women with hypoactive sexual desire disorder established the efficacy and safety basis for FDA approval of bremelanotide, with a subgroup analysis examining consistency of response across patient characteristics. [2]
02
Long-term open-label follow-up
Women who completed the 24-week double-blind trial phase could continue into a 52-week open-label extension; this follow-up assessed long-term safety and efficacy outcomes in the same overall study population. [3]
03
Approved indication, dosing limit, and contraindication per FDA label
Per its FDA label, VYLEESI is indicated only for premenopausal women with acquired, generalized hypoactive sexual desire disorder that is not explained by a co-existing condition, relationship problem, or medication effect; it is not indicated for postmenopausal women or men, and not indicated to enhance sexual performance. The label limits dosing to no more than one 1.75mg dose per 24 hours and no more than 8 doses per month, and lists uncontrolled hypertension or known cardiovascular disease as a contraindication. [4]
03 · Numbers in context
What does dosing evidence actually support?
Clinical evidence comes from the RECONNECT phase 3 program, which studied on-demand subcutaneous dosing of the approved autoinjector formulation in premenopausal women with a specific diagnosed condition, under medical supervision and with a defined maximum dosing frequency [1][2][3]. This trial evidence describes a specific approved drug-device combination and indication; it does not describe or validate self-administered dosing of a research-vial or nasal-spray version of the same peptide.
A study dose is not a personal dose. Population, route, formulation and supervision are part of the result. Online community schedules are not treated here as established clinical protocols.
04 · Safety and limits
What not to overlook
- VYLEESI's approval and trial evidence apply specifically to premenopausal women with a diagnosed condition, using the approved autoinjector at a labeled maximum of 8 doses per month, under medical guidance; it is not indicated for men or postmenopausal women.
- Research-chemical vials and nasal sprays sold as PT-141 are not the approved Vyleesi formulation and were not the product used in the cited trials.
- Per the FDA label, uncontrolled hypertension or known cardiovascular disease is a contraindication, and blood pressure effects were monitored in the trial populations reviewed.
- No trial evidence for a nasal spray delivery format of this peptide was identified in the sources reviewed.
05 · Product distinctions
Names are not interchangeable
Vyleesi is an FDA-approved, prescription, single-use subcutaneous autoinjector containing bremelanotide. Reign Peptide separately sells bremelanotide as a lyophilized powder vial and as a nasal spray, both labeled for research use; these are different delivery formats manufactured by a different party, and no data reviewed here establishes their equivalence to the approved autoinjector.
06 · Handling and storage
Follow validated product instructions
A single water volume, refrigerator temperature or expiry window cannot be assumed for every compound and formulation. Use the exact manufacturer documentation and a validated laboratory procedure. If stability, solvent compatibility or microbiological quality is not documented, those properties remain unverified.
Refrigeration, clear appearance and bacteriostatic water do not make an unverified research product suitable for injection. This guide does not provide a mixing or administration procedure.
The existing concentration calculator checks arithmetic only. It cannot choose a safe dose or establish compatibility, sterility or shelf life.
Reign Peptide · Business disclosure
Research product listings
Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.
Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.
Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.
Supplies and accessories
Compare the actual specifications
Jorge's supply directory includes syringes, alcohol pads, storage cases, travel refrigeration and electrolytes, with separate links for the two travel refrigeration options. Accessory availability is not a recommendation to administer a research compound.
Affiliate disclosure: As an Amazon Associate I earn from qualifying purchases.
Amazon affiliate link
Peptide fridge case
Listing: 63 slots for 3mL bottles, bag only. An organizer is not active refrigeration or a validated storage system.
View on Amazon ↗Amazon affiliate link
Peptide travel case
Medineed travel case with temperature display and two ice packs per listing. Check dimensions and transport requirements.
View on Amazon ↗Questions still worth asking
What remains unresolved?
- Has any published pharmacokinetic study compared nasal spray delivery of bremelanotide to the approved subcutaneous autoinjector?
- What is the efficacy and safety profile of bremelanotide in populations outside the premenopausal women studied in the RECONNECT trials?
Check the source
References and evidence scope
- Review · 2022Bremelanotide for Treatment of Female Hypoactive Sexual Desire ↗
- Human trial · 2022Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide ↗
- Human trial · 2019Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder ↗
- Official label · 2025VYLEESI (bremelanotide) injection, prescribing information ↗
These are the sources reviewed for this page, not an exhaustive systematic review. Related compound research is identified as such. Product links are not scientific references.
Keep reading